CARB-X FUNDS 100TH PROJECT TARGETING ANTIBIOTIC RESISTANCE
CARB-X, a biopharmaceutical accelerator, has awarded US$452.6 million in non-dilutive funding to 100 projects addressing antibiotic resistance since its inception in 2016. The Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has been awarded US$1.06 million to develop a new class of small-molecule inhibitors of bacterial sliding clamp (DnaN), a crucial component of DNA replication machinery. These compounds show promising antibacterial activities against several pathogens causing community-acquired bacterial pneumonia (CABP) and have properties consistent with an oral therapy. CARB-X supports novel approaches to deliver antibiotics that clinicians and patients need, with the aim of offering a workhorse antibiotic for community-acquired infections that will also remove the pressure off antibiotics in the WHO model list of essential medicines. Since 2016, CARB-X has supported R&D projects in 13 countries, with 18 projects advanced into or completed first-in-human clinical trials, 12 remaining active in clinical development, and two diagnostic products reaching the market.
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!